Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Genprex ( (GNPX) ) is now available.
On November 4, 2025, Genprex announced that the European Patent Office intends to grant a patent for Reqorsa® Gene Therapy in combination with PD-1 antibodies for cancer treatment. This potential patent expands on existing patents in several countries and highlights Reqorsa’s potential to enhance current cancer therapies, particularly for lung cancer.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for cancer and diabetes. Its primary product, Reqorsa® Gene Therapy, is being developed to treat lung cancer in combination with approved cancer drugs.
Average Trading Volume: 714,848
Technical Sentiment Signal: Sell
Current Market Cap: $8.65M
See more insights into GNPX stock on TipRanks’ Stock Analysis page.